CombinatoRx has announced the full data on Synavive (CRx-102) phase-II knee osteoarthritis (OA) trial (COMET-1).
Synavive, a dissociated glucocorticoid and prednisolone, provided safe and effective pain relief in knee osteoarthritis in a placebo-controlled phase-II trial.
Efficacy was observed early in treatment and sustained throughout the study in all WOMAC measurement subscales including pain, physical function and stiffness. In addition, combination effects of Synavive were observed in comparison to prednisolone alone, especially in subjects with greater disease burden.
In comparison to prednisolone alone, reduction in hand OA pain was observed early with Synavive and sustained throughout the study.
Kenneth Huttner, Medical Director, CombinatoRx, said: Low-dose prednisolone appears to be effective when combined synergistically with dipyridamole to amplify its anti-inflammatory activity. This suggests that there may be a role for Synavive in the treatment of OA, as it may allow for the use of prednisolone at what appear to be safe but still effective dose levels.